" /> Autologous Anti-MSLN CAR/HLA-A*02-gated Inhibitory Receptor/B2M shRNA-expressing T-lymphocytes A2B694 - CISMeF





Preferred Label : Autologous Anti-MSLN CAR/HLA-A*02-gated Inhibitory Receptor/B2M shRNA-expressing T-lymphocytes A2B694;

NCIt synonyms : Autologous Anti-MSLN Logic-gated CAR T Cells A2B694; Autologous Anti-MSLN Logic-gated Tmod CAR T-cells A2B694; Autologous Anti-MSLN CAR T Cells A2B694; Autologous Tmod CAR T-cells A2B694; Autologous MSLN-directed Logic-gated CAR-T Cells A2B694; Tmod CAR-T Cells A2B694;

NCIt definition : A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector expressing an activating chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) mesothelin (MSLN), a leukocyte immunoglobulin-like receptor 1 (LIR-1)-based inhibitory receptor specific for human leukocyte antigen (HLA)-A*02 (HLA-A*02), and a short hairpin RNA (shRNA) targeting beta-2 microglobulin (B2M; beta2M), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MSLN CAR/HLA-A*02-gated inhibitory receptor/B2M shRNA-expressing T-lymphocytes A2B694 target and bind to MSLN-expressing tumor cells, thereby killing MSLN-expressing tumor cells that have loss of heterozygosity (LOH) for HLA-A*02 protein. The inhibitory receptor specific for HLA-A*02 acts as a self-regulated safety switch that blocks the killing of HLA-A*02-positive MSLN-expressing normal, healthy cells. HLA-A*02 is expressed on normal cells but not on tumor cells due to LOH. The B2M shRNA disrupts the expression of the B2M component of the HLA class I molecule. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.;

Molecule name : A2B-694; A2B 694;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.